Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN
Condition(s):Squamous Cell Carcinoma of the Head and NeckLast Updated:May 31, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Squamous Cell Carcinoma of the Head and NeckLast Updated:May 31, 2023Active, not recruiting
Condition(s):Squamous Cell Carcinoma of the Head and NeckLast Updated:October 23, 2017Completed
Condition(s):Squamous Cell Carcinoma; Carcinoma of Head and/or NeckLast Updated:June 4, 2008Completed
Condition(s):Squamous Cell Carcinoma of Head and NeckLast Updated:October 13, 2023Recruiting
Condition(s):Head and Neck Squamous Cell CarcinomaLast Updated:March 12, 2024Recruiting
Condition(s):Head and Neck Cancer; Squamous Cell Carcinoma of Head and NeckLast Updated:March 8, 2024Recruiting
Condition(s):Squamous Cell Carcinoma of Head and NeckLast Updated:March 12, 2024Recruiting
Condition(s):Squamous Cell Carcinoma of the Head and NeckLast Updated:February 7, 2024Active, not recruiting
Condition(s):Squamous Cell Carcinoma of the Head and NeckLast Updated:March 24, 2023Terminated
Condition(s):Squamous Cell Carcinoma of the Head and NeckLast Updated:September 3, 2014Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.